Cell and gene therapy companies cannot secure sustainable funding models to commercialize breakthrough treatments

Biotech companies developing cell and gene therapies face a critical funding crisis where the cost of treatment development far exceeds what payers (insurance, government, patients) can afford, causing promising therapies to stall in development pipelines. Current reimbursement models, venture capital cycles, and payment infrastructure are fundamentally misaligned with the economics of these therapies, forcing companies to choose between abandoning innovation or facing financial collapse.